ABSTRACT

Introduction

Accurate determination of the aberrantly expressed biomarkers such as human epidermal growth factor receptor 2 (HER2), carcinoembryonic antigen (CEA), platelet-derived growth factor (PDGF), mucin 1 (MUC1), and vascular endothelial growth factor VEGF₁₆₅ have played an essential role in the clinical management of the breast cancer. Assessment of these cancer-specific biomarkers has conventionally relied on time-taking methods like the enzyme-linked immunosorbent assay and immunohistochemistry. However, recent development in the aptamer-based diagnostics has allowed developing tools that may substitute the conventional means of biomarker assessment in breast cancer. Adopting the aptamer-based diagnostic tools (aptasensors) to clinical practices will depend on their analytical performance on clinical samples.

Areas covered

In this review, we provide an overview of the analytical merits of HER2, CEA, PDGF, MUC1, and VEGF₁₆₅ aptasensors. Scopus and Pubmed databases were searched for studies reporting aptasensor development for the listed breast cancer biomarkers in the past one decade. Linearity, detection limit, and response time are emphasized.

Expert opinion

In our opinion, aptasensors have proven to be on a par with the antibody-based methods for detection of various breast cancer biomarkers. Though robust validation of the aptasensors on significant sample size is required, their ability to detect pathophysiological range of biomarkers suggest the possibility of future clinical adoption.

中文翻译：

---

基于适体的乳腺癌生物标志物传感：对分析品质因数的全面回顾

摘要

介绍

准确测定人表皮生长因子受体2（HER2）、癌胚抗原（CEA）、血小板衍生生长因子（PDGF）、粘蛋白1（MUC1）、血管内皮生长因子VEGF ₁₆₅等异常表达的生物标志物在乳腺癌的临床治疗中发挥着重要作用。对这些癌症特异性生物标志物的评估通常依赖于耗时的方法，如酶联免疫吸附试验和免疫组织化学。然而，基于适配体的诊断的最新发展允许开发可以替代乳腺癌生物标志物评估的传统方法的工具。在临床实践中采用基于适配体的诊断工具（适配体传感器）将取决于它们对临床样本的分析性能。

涵盖的领域

在这篇综述中，我们概述了 HER2、CEA、PDGF、MUC1 和 VEGF ₁₆₅适体传感器的分析优点。搜索 Scopus 和 Pubmed 数据库中的研究报告了过去十年中列出的乳腺癌生物标志物的适体传感器发展情况。强调线性、检测限和响应时间。

专家意见

在我们看来，适体传感器已被证明与基于抗体的检测各种乳腺癌生物标志物的方法相当。尽管需要在大量样本上对适体传感器进行强有力的验证，但它们检测生物标志物病理生理范围的能力表明未来临床采用的可能性。